Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00467077 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

NETWORK

Sponsor class

Stopped Protocol was closed due to slow accrual.

Conditions

Kidney Cancer

Interventions

BIOLOGICAL: PEG-interferon alfa-2b
DRUG: gefitinib

Sponsor

California Cancer Consortium

Collaborators

[object Object]